A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
Sang Hee Park,1 Xue Han,2 Francis Lobo,2 Sakina Nanji,1 Dipen Patel1 1Modeling and Meta-Analysis, Pharmerit International, Bethesda, MD, USA; 2WW HEOR Markets-US, Bristol-Myers Squibb Company, Lawrenceville, NJ, USACorrespondence: Xue HanBristol-Myers Squibb Company, 3401 Princeton Pike, Lawrencevil...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-10-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-cost-per-responder-model-for-abatacept-versus-adalimumab-among-rheum-peer-reviewed-article-CEOR |